Lipid Metabolism Disorders  >>  evacetrapib (LY2484595)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
evacetrapib (LY2484595) / Eli Lilly
NCT01105975 / 2009-017479-29: A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

Checkmark AHA 2014
Nov 2014 - Nov 2014: AHA 2014
Checkmark In patients With High LDL-C or Low HDL-C
Oct 2013 - Oct 2013: In patients With High LDL-C or Low HDL-C
Completed
2
398
US, Europe
LY2484595, Atorvastatin, Simvastatin, Rosuvastatin, Placebo for LY2484595, Placebo for Statins
Eli Lilly and Company
Dyslipidemia
06/11
06/11
NCT01375075: A Study of LY2484595 in Japanese Subjects

Checkmark
May 2014 - May 2014: 
Completed
2
165
Japan
LY2484595, Placebo, Atorvastatin
Eli Lilly and Company
Dyslipidemias
03/12
03/12

Download Options